Heidelberg Pharma AG (FSE: HPHA) and its partner Huadong Medicine Co., Ltd. have received clinical trial approval from the China National Medical Products Administration (NMPA) for a Phase Ib/II study evaluating pamlectabart tismanitin (HDP-101), a novel BCMA-targeting antibody-drug conjugate (ADC), in combination regimens for relapsed/refractory multiple myeloma. This approval underscores the strategic importance of combination therapies in Heidelberg Pharma's clinical development strategy and highlights the growing role of China in global oncology trials.
The trial will assess the safety, tolerability, and preliminary efficacy of pamlectabart tismanitin combined with either pomalidomide and dexamethasone or daratumumab and dexamethasone in adult patients who have received at least one prior line of therapy. Huadong Medicine will conduct the trial in China and bear the development costs, consistent with the exclusive rights it holds for HDP-101 across 20 Asian markets under the partnership established in February 2022. This collaboration also made Huadong Medicine the second-largest shareholder of Heidelberg Pharma, reflecting a deep mutual commitment.
The approval is particularly significant given the current clinical landscape. Pamlectabart tismanitin is already being evaluated as a monotherapy in an ongoing Phase I/IIa trial in the U.S. and Europe since 2022, with a recommended Phase II dose established. In March 2026, a monotherapy bridging study was initiated in China, and now this combination trial will further expand the clinical program. The drug has received Orphan Drug Designation (ODD) from the U.S. FDA in March 2024 and Fast Track Designation (FTD) in October 2025, underscoring its potential to address unmet needs in multiple myeloma.
The rationale for combining HDP-101 with established regimens is to potentially enhance efficacy and overcome resistance mechanisms, which could allow the therapy to be used in earlier lines of treatment and in broader patient populations. This approach aligns with current trends in oncology, where combination therapies are increasingly the standard of care. By evaluating these combinations in China, the trial may generate data that supports global registration and provides access to a large patient population.
Heidelberg Pharma's ATAC technology, derived from amanitin, a toxin from the green death cap mushroom, represents a novel mechanism of action. The company's lead candidate, HDP-101, targets BCMA, a protein highly expressed on myeloma cells, and has shown promise in early trials. The NMPA approval not only validates the potential of this approach but also strengthens Heidelberg Pharma's position in the competitive ADC landscape.
This development could have significant implications for patients with relapsed/refractory multiple myeloma, a condition with poor prognosis and limited treatment options. If the combination therapies prove successful, they could offer new hope and potentially become a standard of care. Moreover, the collaboration with Huadong Medicine facilitates a faster and more efficient path to market in Asia, a region with high unmet medical need.
In summary, the NMPA approval for HDP-101 combination therapy is a major milestone for Heidelberg Pharma and Huadong Medicine, advancing the clinical development of a promising ADC and potentially expanding treatment options for multiple myeloma patients worldwide. As the trial progresses, the oncology community will be watching closely for the results, which could reshape treatment paradigms in the near future.
